Drug overlaps, shortages may complicate Teva bid for Mylan

April 24, 2015 8:58 PM

2 0

Drug overlaps, shortages may complicate Teva bid for Mylan

NEW YORK (Reuters) - Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.

Teva, the world’s largest generic drugmaker, made its $40 billion offer public on Tuesday and quickly signaled it was ready to sell some overlapping assets to win antitrust approval for a deal.

Read more

To category page

Loading...